American Heart Journal
Volume 157, Issue 6 , Pages 1018-1025, June 2009

Influence of coronary angiography on the utilization of therapies in patients with acute heart failure syndromes: Findings from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF)

  • James D. Flaherty, MD

      Affiliations

    • Northwestern University, Chicago, IL
  • ,
  • Joseph S. Rossi, MD

      Affiliations

    • University of North Carolina, Chapel Hill, NC
  • ,
  • Gregg C. Fonarow, MD

      Affiliations

    • University of California Los Angeles Medical Center, Los Angeles, CA
    • Corresponding Author InformationReprint requests: Gregg C. Fonarow, MD, UCLA Division of Cardiology, 10833 LeConte Avenue, Los Angeles, CA 90095-1679.
  • ,
  • Eduardo Nunez, MD

      Affiliations

    • GlaxoSmithKline, Philadelphia, PA
  • ,
  • Wendy Gattis Stough, PharmD

      Affiliations

    • Duke University Medical Center, Durham, and Campbell University School of Pharmacy, Research Triangle Park, NC
  • ,
  • William T. Abraham, MD

      Affiliations

    • The Ohio State University, Columbus, OH
  • ,
  • Nancy M. Albert, PhD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, OH
  • ,
  • Barry H. Greenberg, MD

      Affiliations

    • University of California San Diego, San Diego, CA
  • ,
  • Christopher M. O'Connor, MD

      Affiliations

    • Duke University Medical Center, Durham, NC
  • ,
  • Clyde W. Yancy, MD

      Affiliations

    • Baylor University Medical Center, Dallas, TX
  • ,
  • James B. Young, MD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, OH
  • ,
  • Charles J. Davidson, MD

      Affiliations

    • Northwestern University, Chicago, IL
  • ,
  • Mihai Gheorghiade, MD

      Affiliations

    • Northwestern University, Chicago, IL

Received 18 January 2009; accepted 6 March 2009. published online 24 April 2009.

Background

Most patients hospitalized for acute heart failure syndromes (AHFS) carry a diagnosis of coronary artery disease (CAD), but coronary angiography is infrequently performed. This purpose of this study was to determine the influence of coronary angiography on use of therapeutics and early postdischarge outcomes in patients with AHFS.

Methods

The Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure program enrolled 48,612 patients admitted with AHFS at 259 academic and community hospitals throughout the United States Inhospital treatments and outcomes were tracked in all patients and postdischarge outcomes in a prespecified 10% sample. Outcome data were prospectively collected and analyzed according to whether coronary angiography was performed during the index hospitalization and whether a patient had CAD.

Results

Overall, 8.7% of all patients underwent inhospital angiography. Among patients with CAD who underwent angiography, 27.5% underwent inhospital myocardial revascularization. At the time of discharge, patients with CAD who underwent angiography were significantly more likely to be receiving aspirin (68.9% vs 50.3%, P < .0001), statins (56.6% vs 40.6%, P < .0001), β-blockers (78.6% vs 67.5%, P < .0001), and angiotensin-converting enzyme inhibitors (64.9% vs 51.5%, P < .0001). In patients with AHFS and CAD, the use of inhospital angiography was associated with significantly lower mortality and rehospitalization risk in the first 60 to 90 days post hospital discharge after adjustment for multiple comorbidities and patient factors: mortality (HR 0.31 [95% CI 0.14-0.70], P = .004) and death or rehospitalization (OR 0.65 [95% CI 0.50-0.86], P = .003). There were no significant differences in any of these outcomes in patients with AHFS and a nonischemic etiology based the performance of inhospital angiography.

Conclusions

The performance of inhospital angiography on patients with AHFS and CAD is associated with an increased use of aspirin, statins, β-blockers, angiotensin-converting enzyme (ACE) inhibitors and myocardial revascularization. This corresponded with significantly lower rates of death, rehospitalization, and death or rehospitalization at 60 to 90 days post discharge.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 Clinical Trial.gov identifier: NCT00344513.

 Funding: OPTIMIZE-HF and this study were supported by GlaxoSmithKline, Philadelphia, PA.

 Dr William S. Weintraub served as guest editor for this manuscript.

PII: S0002-8703(09)00205-1

doi:10.1016/j.ahj.2009.03.011

American Heart Journal
Volume 157, Issue 6 , Pages 1018-1025, June 2009